Boston Scientific (NYSE:BSX) 주식

BOSTON SCIENTIFIC CORP

Boston Scientific

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Stock-Whisper-Index-Logo-6-copy copy

Exclusives

Trading Ideas

MELI

SOFI

UBER

매주, 벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 우버, 보스톤 사이언티픽, EMCOR, 메르카도 리브레 및 소파이

Wall-Street-ai7-1

Analyst Color

Earnings

Equities

Large Cap

Mid Cap

Tech

ETFs

AMGN

AVGO

AZEK

DELL

Janus Henderson Group plc Ordinary Shares

KVYO

MNDY

NVDA

QGEN

SNOW

TOST

UPST

3분기 실적 시즌이 다가오면서, 골드만삭스는 투자자들이 재무 실적을 통해 수익을 올릴 수 있는 주요 주식 기회를 식별한 노트를 발표했다. 애널리스트 존 마샬(John Marshall)과 그의 팀은 목요일에 18개의 주식이 실적 상향 조정의 혜택을 받을 가능성이 있고, 7개의 주식은 하향 조정의 영향을 받을 가능성이 있다고 강조했다.

이번 실적 시즌에 매수할 주식 18개, 매도할 주식 7개: 골드만삭스는 올해를 &#39;주식 선택자의 해&#39;

Tesla's Sky-High Surge

News

Previews

ABBV

AGYS

ASML

BJRI

CHKP

CHTR

CMCSA

DECK

GATX

GOOG

GOOGL

JNPR

NFLX

NXPI

ODFL

ORLY

SKYW

SPOT

TSLA

VRSN

S&amp;P 500 기업들 중 약 14%가 6월 분기 실적을 발표했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.

테슬라, 알파벳, GM 및 포드가 이번 주 실적 발표 주도하며 상승세 유지 위해 고군분투

Boston Scientific Corporation Common Stock

Boston Scientific Corp

Basilisk - United States Dollar

BELO SUN MINING CORP ORD by Belo Sun Mining Corp.

Belo Sun Mining Corp

Boston Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) short percent of float has risen 6.6% since its last report. The company recently reported that it has 16.75 million shares sold short, which is 1.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Boston Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749063629_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Boston Scientific has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Boston Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Boston Scientific's peer group average for short interest as a percentage of float is 5.51%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is Boston Scientific Gaining or Losing Market Support?

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 15 years by 9.52% on an annualized basis producing an average annual return of 21.59%. Currently, Boston Scientific has a market capitalization of $155.15 billion. 
Buying $100 In BSX: If an investor had bought $100 of BSX stock 15 years ago, it would be worth $1,853.19 today based on a price of $104.90 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748872815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

In the current market session, Boston Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) stock price is at $104.20, after a 0.29% drop. However, over the past month, the company's stock increased by 0.10%, and in the past year, by 39.11%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1748635237_0.png" alt="Past Year Chart" />

<h3>Boston Scientific P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Boston Scientific has a better P/E ratio of 76.28 than the aggregate P/E ratio of 53.33 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that Boston Scientific Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748635237_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

P/E Ratio Insights for Boston Scientific

Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) is pulling the plug on its ACURATE neo2 and <a href="https://www.benzinga.com/general/health-care">Prime aortic valve systems</a>.
What Happened: The medical technology giant halted global sales and abandoned regulatory pursuits—including a long-sought FDA approval—after escalating demands from health authorities rendered the effort too costly. 
Despite the setback, the Marlborough, Massachusetts-based company signaled confidence in its broader portfolio, affirming that it remains on track to hit its financial targets for the quarter and full year.
Also, Boston Scientific is no longer pursuing U.S. Food And Drug Administration (FDA) approval for ACURATE.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry</a>
The company based its decision on recent discussions with regulators. There have been increased clinical and regulatory requirements to maintain regulatory approvals in global markets.
The additional resources and investments needed to satisfy these requirements are prohibitive for the company.
Boston Scientific, in an SEC <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000885725/000088572525000033/bsx-20250528.htm">filing</a>, stated that it expects to achieve organic sales guidance for the second quarter and 2025.
<ul class="wp-block-list">
<li>Outlook: Boston Scientific forecasts net sales growth of approximately 15%-17% in 2025 on a reported basis and around 12%-14% on an organic basis, compared to prior guidance of 12.5%-14.5% and <a href="https://www.benzinga.com/general/health-care/25/04/44952308/boston-scientific-raises-annual-outlook-after-strong-heart-devices-sales-in-q1-announces-cfo-transition" target="_blank" rel="noreferrer noopener">10%-12%, respectively</a>.</li>
<li>The company estimates 2025 adjusted EPS of $2.87-$2.94 compared to prior guidance of $2.80-$2.87 and the consensus of $2.86.</li>
<li>The company estimates second quarter 2025 net sales growth of approximately 17.5%-19.5% on a reported basis and approximately 13%-15% on an organic basis, with adjusted EPS of 71-73 cents compared to consensus of 71 cents.</li>
</ul>
The company is not reaffirming its second quarter and full year 2025 GAAP EPS guidance and expects to provide more information during its second quarter 2025 earnings call.
<ul class="wp-block-list">
<li>Boston Scientific estimated 2025 GAAP earnings of $1.86-$1.93 per share and second-quarter earnings of $0.45&nbsp;to&nbsp;$0.47 per share.</li>
</ul>
Price Action: Boston Scientific stock is down 0.98% at $105.13 at the last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45643848/macys-feels-tariffs-and-consumer-spending-heat-cuts-profit-forecast" target="_blank" rel="noreferrer noopener">Macy&#8217;s Feels Tariffs And Consumer Spending Heat, Cuts Profit Forecast</a></li>
</ul>
Image: Shutterstock

Health Care

Movers

General

Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook

Needham analyst Mike Matson reiterates Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and maintains $115 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Boston Scientific, Maintains $115 Price Target

Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $119 to $125.

Citigroup Maintains Buy on Boston Scientific, Raises Price Target to $125

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$90.00</td>
<td>$286.6K</td>
<td>20.5K</td>
<td>19.1K</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$320.00</td>
<td>$82.5K</td>
<td>2.3K</td>
<td>5.2K</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$290.00</td>
<td>$330.7K</td>
<td>64</td>
<td>1.3K</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$50.00</td>
<td>$81.0K</td>
<td>573</td>
<td>292</td>
</tr>
<tr>
<td>OCUL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$10.00</td>
<td>$32.5K</td>
<td>60</td>
<td>190</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$810.00</td>
<td>$35.5K</td>
<td>12</td>
<td>169</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$45.00</td>
<td>$43.0K</td>
<td>3.5K</td>
<td>113</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$60.00</td>
<td>$35.0K</td>
<td>2.4K</td>
<td>85</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$175.00</td>
<td>$93.8K</td>
<td>384</td>
<td>59</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$40.00</td>
<td>$29.9K</td>
<td>776</td>
<td>58</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a put option trade that happens to be bearish, expiring in 31 day(s) on June 20, 2025. This event was a transfer of 11467 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $286.6K, with a price of $25.0 per contract. There were 20532 open contracts at this strike prior to today, and today 19153 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option trade with bearish sentiment. It expires in 10 day(s) on May 30, 2025. Parties traded 60 contract(s) at a $320.00 strike. The total cost received by the writing party (or parties) was $82.5K, with a price of $1375.0 per contract. There were 2315 open contracts at this strike prior to today, and today 5276 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option trade with bullish sentiment. It expires in 10 day(s) on May 30, 2025. Parties traded 1350 contract(s) at a $290.00 strike. The total cost received by the writing party (or parties) was $330.7K, with a price of $245.0 per contract. There were 64 open contracts at this strike prior to today, and today 1371 contract(s) were bought and sold. 
• Regarding AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we observe a call option sweep with bullish sentiment. It expires in 31 day(s) on June 20, 2025. Parties traded 270 contract(s) at a $50.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $81.0K, with a price of $300.0 per contract. There were 573 open contracts at this strike prior to today, and today 292 contract(s) were bought and sold. 
• Regarding OCUL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>), we observe a put option trade with bearish sentiment. It expires in 213 day(s) on December 19, 2025. Parties traded 100 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $32.5K, with a price of $325.0 per contract. There were 60 open contracts at this strike prior to today, and today 190 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bearish, expiring in 38 day(s) on June 27, 2025. This event was a transfer of 24 contract(s) at a $810.00 strike. The total cost received by the writing party (or parties) was $35.5K, with a price of $1480.0 per contract. There were 12 open contracts at this strike prior to today, and today 169 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a put option trade with bearish sentiment. It expires in 304 day(s) on March 20, 2026. Parties traded 104 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $43.0K, with a price of $414.0 per contract. There were 3563 open contracts at this strike prior to today, and today 113 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with neutral sentiment. It expires in 87 day(s) on August 15, 2025. Parties traded 25 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1400.0 per contract. There were 2475 open contracts at this strike prior to today, and today 85 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bearish sentiment. It expires in 87 day(s) on August 15, 2025. Parties traded 59 contract(s) at a $175.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $93.8K, with a price of $1590.0 per contract. There were 384 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be bullish, expiring in 605 day(s) on January 15, 2027. This event was a transfer of 9 contract(s) at a $40.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $29.9K, with a price of $3330.0 per contract. There were 776 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AKRO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

OCUL

10 Health Care Stocks With Whale Alerts In Today's Session

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 15 years by 8.95% on an annualized basis producing an average annual return of 21.03%. Currently, Boston Scientific has a market capitalization of $156.39 billion. 
Buying $1000 In BSX: If an investor had bought $1000 of BSX stock 15 years ago, it would be worth $17,333.49 today based on a price of $105.73 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747756818_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today

During the last three months, 9 analysts shared their evaluations of Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Boston Scientific, revealing an average target of $117.78, a high estimate of $125.00, and a low estimate of $112.00. This current average reflects an increase of 1.87% from the previous average price target of $115.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1747422080_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Boston Scientific. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$117.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$113.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$113.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Boston Scientific. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Boston Scientific compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Boston Scientific's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Boston Scientific's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BSX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Boston Scientific analyst ratings.</a>
<h2>Get to Know Boston Scientific Better</h2>
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
<h3>Financial Insights: Boston Scientific</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3M period, Boston Scientific showcased positive performance, achieving a revenue growth rate of 20.93% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Boston Scientific's net margin excels beyond industry benchmarks, reaching 14.45%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Boston Scientific's ROE excels beyond industry benchmarks, reaching 3.06%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Boston Scientific's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.69%, the company showcases efficient use of assets and strong financial health.
Debt Management: Boston Scientific's debt-to-equity ratio is below the industry average at 0.53, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 9 Analyst Projections For Boston Scientific

Morgan Stanley analyst Patrick Wood maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Overweight and raises the price target from $120 to $125.

Morgan Stanley Maintains Overweight on Boston Scientific, Raises Price Target to $125

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 15 years by 8.98% on an annualized basis producing an average annual return of 20.36%. Currently, Boston Scientific has a market capitalization of $150.91 billion. 
Buying $100 In BSX: If an investor had bought $100 of BSX stock 15 years ago, it would be worth $1,560.09 today based on a price of $102.03 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746116414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today

Barclays analyst Matt Miksic maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Overweight and raises the price target from $118 to $125.

Barclays Maintains Overweight on Boston Scientific, Raises Price Target to $125

Trial achieves positive results in the treatment of persistent atrial fibrillation
MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ --&nbsp;Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) today announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the FARAPULSE&#x2122; Pulsed Field Ablation (PFA) System&#x2A; and adjunctive use of the FARAPOINT&#x2122; PFA Catheter in patients with persistent atrial fibrillation (AF). &nbsp;Key findings from the study were presented at the second annual PFA Live Case Summit in San Diego and simultaneously published in <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4411722-1&amp;h=2061933693&amp;u=https%3A%2F%2Fwww.ahajournals.org%2Fdoi%2F10.1161%2FCIRCULATIONAHA.125.074485&amp;a=Circulation">Circulation</a>.
Persistent AF, which accounts for approximately 25%1 of all AF cases, is an abnormal, rapid heartbeat that lasts for at least seven days in a row and can lead to complications such as blood clots, stroke and heart failure. The second phase of the ADVANTAGE AF trial studied the FARAWAVE&#x2122; PFA Catheter for both pulmonary vein isolation (PVI) and posterior wall ablation (PWA) and the FARAPOINT PFA Catheter for cavotricuspid isthmus (CTI) ablation to treat typical atrial flutter (AFL), a type of heart rhythm disorder. All patients in the trial were continuously monitored after their procedure with the LUX-Dx&#x2122; Insertable Cardiac Monitor (ICM) System, which is designed to detect recurrence of cardiac arrhythmias and assess AF burden. Findings from the trial met all pre-specified safety and effectiveness endpoints and demonstrated:
<ul>
<li>73.4% freedom from AF, AFL and atrial tachycardia (AT), which exceeded the performance goal of 40% or higher.</li>
<li>A safety event rate of 2.4% and no reports of pulmonary vein stenosis, atrio-esophageal fistula or phrenic nerve palsy which met the performance goal of 12% or lower.</li>
<li>81.0% freedom from symptomatic documented AF recurrence, which is defined as arrhythmia, clinical intervention or use of escalated or new Class I/III anti-arrhythmic drugs.</li>
<li>71.6% of patients had virtually no atrial arrhythmia (AA) burden, in which data shows lower AA burden can be associated with fewer clinical interventions and improvements in quality of life and 52% of patients had no residual AA events after the blanking period.</li>
<li>96.4% of patients treated with the FARAPOINT PFA Catheter had no recurrence of AFL.</li>
</ul>
Boston Scientific anticipates U.S. Food and Drug Administration approval to expand the instructions for use labeling for the FARAPULSE PFA System to include persistent AF as well as European and U.S. regulatory approvals for the FARAPOINT PFA Catheter in the second half of 2025.
 &nbsp;

Boston Scientific Says Second Phase Of ADVANTAGE AF Clinical Trial Of FARAPULSE Pulsed Field Ablation System Meets Primary Safety And Efficacy Endpoints

Needham analyst Mike Matson maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $113 to $115.

Needham Maintains Buy on Boston Scientific, Raises Price Target to $115

Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) posted better-than-expected earnings for the <a href="https://www.benzinga.com/quote/BSX/earnings">first quarter on Wednesday</a>.
The company reported first-quarter 2025 revenues of $4.66 billion, beating the consensus estimate of $4.57 billion. The company earned an adjusted EPS of 75 cents, beating the consensus of 67 cents and exceeding the management guidance of 66-68 cents.
"We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio," said Mike Mahoney, chairman and chief executive officer of Boston Scientific. "We remain well-positioned for the future as we continue to focus on meaningful innovation, clinical science and the execution of our category leadership strategy to drive differentiated growth and performance for the long-term."
Boston Scientific said it sees net sales growth of approximately 15%-17% in 2025 on a reported basis and around 12%-14% on an organic basis, compared to prior guidance of 12.5%-14.5% and 10%-12%, respectively.
The company estimates 2025 adjusted EPS of $2.87-$2.94 compared to prior guidance of $2.80-$2.87 and the consensus of $2.86.
Boston Scientific shares gained 2.4% to trade at $101.24 on Thursday.
These analysts made changes to their price targets on Boston Scientific following earnings announcement.
<ul>
<li>Baird analyst David Rescott maintained Boston Scientific with an Outperform rating and raised the price target from $115 to $120.</li>
<li>Evercore ISI Group analyst Vijay Kumar maintained the stock with an Outperform rating and increased the price target from $110 to $112.</li>
<li>Truist Securities analyst Richard Newitter maintained Boston Scientific with a Buy rating and raised the price target from $113 to $117.</li>
<li>RBC Capital analyst Shagun Singh maintained Boston Scientific with an Outperform rating and raised the price target from $116 to $120.</li>
</ul>
Considering buying BSX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141148/image-159-1024x611.png" alt="" class="wp-image-887296" style="width:575px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141148/image-159-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141148/image-159-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141148/image-159-768x458.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141148/image-159.png 1100w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44948767/top-2-consumer-stocks-that-may-implode-this-month">Top 2 Consumer Stocks That May Implode This Month</a> </li>
</ul>
Photo via Shutterstock

Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results

RBC Capital analyst Shagun Singh maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform and raises the price target from $116 to $120.

RBC Capital Maintains Outperform on Boston Scientific, Raises Price Target to $120

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $113 to $117.

Truist Securities Maintains Buy on Boston Scientific, Raises Price Target to $117

Evercore ISI Group analyst Vijay Kumar maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform and raises the price target from $110 to $112.

Evercore ISI Group Maintains Outperform on Boston Scientific, Raises Price Target to $112

Baird analyst David Rescott maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform and raises the price target from $115 to $120.

Baird Maintains Outperform on Boston Scientific, Raises Price Target to $120

Risk-on sentiment dominated Wall Street on Wednesday, as upbeat earnings reports and conciliatory messages from the Trump administration h<a href="https://www.benzinga.com/markets">elped lift investor confidence.</a>
The administration eased market fears on two major fronts that have recently weighed heavily on sentiment. On the trade front, tensions with China appeared to thaw, with reports suggesting the White House is considering reducing tariffs on certain categories of goods.
U.S. Treasury Secretary Scott Bessent added fuel to the rally, stating U.S.-China tariffs are unsustainable and will likely need to be lowered to facilitate meaningful negotiations.
Meanwhile, President Donald Trump offered an abrupt shift in tone toward Federal Reserve Chair Jerome Powell, saying he has no intention to fire him, a remark that helped calm concerns over political interference in monetary policy.
By midday in New York, the S&amp;P 500 was up by nearly 2%, though it had earlier climbed even higher. The Nasdaq 100 outperformed with a 2.5% gain, driven by strength in Magnificent Seven stocks.
Trump's pivot on Powell pushed Treasury yields lower across the curve, with the 30-year yield falling five basis points to 4.83%, after briefly topping 4.90% the previous day.
On the macro front, flash Purchasing Managers&#8217; Index surveys revealed slowing growth momentum in the U.S. economy, as the services sector decelerated sharply following the impact <a href="https://www.benzinga.com/government/regulations/25/04/44952395/us-business-activity-growth-slows-in-april-as-services-suffer-tariff-shock-markets-rally-as-trade-war-cools">of recent tariff shocks.</a>
The U.S. dollar strengthened, while gold plunged 2.6%, heading for its worst session since November.
Oil prices dropped more than 2% following speculation that OPEC+ may announce a new output hike as early as next month.
Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) held steady around $93,000.
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
<td>1-day %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,732.09</td>
<td>+455.68</td>
<td>2.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,926.45</td>
<td>+37.40</td>
<td>2.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,384.67</td>
<td>+96.91</td>
<td>1.8%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,724.87</td>
<td>+537.89</td>
<td>1.4%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:35 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.9% to $537.35.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 1.4% to $397.79.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 2.7% to $456.50.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 2.1% to $191.47.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 3.44%; the&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 1.2%.</li>
</ul>
<h1 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h1>
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) jumped 6.6% despite falling short on both earnings and revenue expectations, as CEO Elon Musk reassured investors by pledging to scale back his involvement with DOGE and refocus on the company.</li>
</ul>
Other stocks reacting to earnings report included: 
<ul>
<li>Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>): up 2.8%</li>
<li>Chubb Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>): down 2.6%</li>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>): up 4.6%</li>
<li>Steel Dynamics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>): up 4.7%</li>
<li>EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>): up 3%</li>
<li>Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>): down 1.7%</li>
<li>Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>): down 4.3%</li>
<li>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>): down 14.4%​</li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>): down 0.5%</li>
<li>Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>): up 2.6%</li>
<li>NextEra Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>): up 1%</li>
<li>Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>): up 4.8%</li>
<li>General Dynamics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>): down 3.4%</li>
<li>Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): up 5.7%</li>
<li>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>): up 1.4%</li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>): down 3.8%</li>
<li>TE Connectivity Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>): up 2.7%</li>
<li>Amphenol Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>): up 9.9%</li>
<li>AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>): up 0.8%</li>
<li>Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>): up 1.3%</li>
<li>Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>): up 7.2%</li>
<li>Masco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>): down 2.1%</li>
<li>Avery Dennison Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>): down 2.4%</li>
<li>Lennox International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>): down 8.2%</li>
<li>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>): up 5.2%</li>
<li>Teledyne Technologies Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>): down 1.7%</li>
<li>Otis Worldwide Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>): down 6%​</li>
</ul>
<ul>
<li>Stocks slated to report earnings after the bell include Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), O'Reilly Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>), Raymond James Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>), Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), Texas Instruments Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>), ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), Lam Research Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), Resmed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>), International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), Rollins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>), United Rentals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>), Tyler Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>), Edwards Lifesciences Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>), and Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>).</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44948932/goldman-sachs-backs-copper-tariff-trade-if-trump-slaps-25-duty-on-us-imports">Goldman Sachs Backs &#8216;Copper Tariff Trade&#8217; If Trump Slaps 25% Duty On US Imports</a></li>
</ul>
Photo: Shutterstock

Government

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Economics

Federal Reserve

$BTC

SPDR Dow Jones Industrial Average ETF Trust

ENPH

ISRG

LRCX

OTIS

STLD

Select Sector SPDR-Consumer Discretionary

Stocks Surge On China Tariff Hopes, Tesla Jumps, Gold Loses Shine: What's Driving Markets Wednesday?

Press Releases

UroGen Pharma Ltd. (NASDAQ: URGN), CS Diagnostics Corp. (OTCQB: CSDX) and Boston Scientific (NYSE: BSX) Advancing Cancer Treatment Technology – More Stocks Inside

Comments

Boston Scientific

뉴스

파트너 / 기고자

벤징가 글로벌